Ani Pharmaceuticals (ANIP)
Ani Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
3.5M
Short interest
settlement 2026-10-15
10.1
Days to cover
+2.9 days vs prior
56.5%
Short share of volume
2026-11-02
16
Fails to deliver
settlement 2026-10-09
Fri 6 Nov
Next earnings
estimated date
-$2.2M
Insider flow, 90 days
0 buys, 11 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ANIP is 3,472,078 shares, up 981,912 shares over the last month. Over the last 48 readings it ranged from 1,839,789 shares (29 November 2024) to 3,621,862 shares (15 May 2026). The latest reading sits at the top of that range. At the reported average volume of 344K shares a day that is 10.1 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/anip" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 3,472,078 | -0.6% | 343,760 | 10.10 |
| 2026-09-30 | 3,491,281 | +40.2% | 487,356 | 7.16 |
| 2026-09-15 | 2,490,166 | -26.0% | 334,880 | 7.44 |
| 2026-08-31 | 3,364,919 | -1.6% | 364,912 | 9.22 |
| 2026-08-14 | 3,420,781 | +46.6% | 464,263 | 7.37 |
| 2026-07-31 | 2,334,112 | -30.8% | 252,428 | 9.25 |
| 2026-07-15 | 3,371,249 | -2.1% | 307,319 | 10.97 |
| 2026-06-30 | 3,442,249 | +7.5% | 365,430 | 9.42 |
| 2026-06-15 | 3,201,694 | -3.7% | 293,393 | 10.91 |
| 2026-05-29 | 3,324,397 | -8.2% | 336,455 | 9.88 |
| 2026-05-15 | 3,621,862 | +1.7% | 469,503 | 7.71 |
| 2026-04-30 | 3,562,734 | +2.0% | 274,930 | 12.96 |
| 2026-04-15 | 3,491,485 | -2.6% | 395,999 | 8.82 |
| 2026-03-31 | 3,584,301 | -0.5% | 298,185 | 12.02 |
| 2026-03-13 | 3,603,758 | +2.1% | 456,720 | 7.89 |
| 2026-02-27 | 3,527,857 | +2.8% | 294,477 | 11.98 |
| 2026-02-13 | 3,430,732 | -1.2% | 337,570 | 10.16 |
| 2026-01-30 | 3,473,308 | +18.0% | 497,363 | 6.98 |
| 2026-01-15 | 2,944,314 | -0.6% | 621,888 | 4.73 |
| 2025-12-31 | 2,962,977 | +11.0% | 427,271 | 6.93 |
| 2025-12-15 | 2,668,488 | -6.3% | 389,729 | 6.85 |
| 2025-11-28 | 2,846,459 | +14.5% | 481,606 | 5.91 |
| 2025-11-14 | 2,485,416 | -0.8% | 414,754 | 5.99 |
| 2025-10-31 | 2,504,638 | +5.4% | 394,924 | 6.34 |
| 2025-10-15 | 2,375,573 | +1.8% | 257,670 | 9.22 |
| 2025-09-30 | 2,333,543 | +13.9% | 338,000 | 6.90 |
| 2025-09-15 | 2,048,917 | +0.3% | 402,047 | 5.10 |
| 2025-08-29 | 2,042,382 | -7.2% | 470,728 | 4.34 |
| 2025-08-15 | 2,201,172 | -0.4% | 951,301 | 2.31 |
| 2025-07-31 | 2,209,541 | +3.9% | 343,187 | 6.44 |
| 2025-07-15 | 2,126,010 | +6.0% | 251,303 | 8.46 |
| 2025-06-30 | 2,005,000 | -0.4% | 287,420 | 6.98 |
| 2025-06-13 | 2,013,161 | +5.8% | 303,194 | 6.64 |
| 2025-05-30 | 1,903,500 | +2.3% | 303,915 | 6.26 |
| 2025-05-15 | 1,861,539 | -6.8% | 545,813 | 3.41 |
| 2025-04-30 | 1,996,967 | -15.2% | 363,572 | 5.49 |
| 2025-04-15 | 2,355,244 | -10.7% | 442,469 | 5.32 |
| 2025-03-31 | 2,637,837 | +2.3% | 374,761 | 7.04 |
| 2025-03-14 | 2,578,433 | +0.9% | 359,494 | 7.17 |
| 2025-02-28 | 2,555,223 | -0.1% | 294,601 | 8.67 |
| 2025-02-14 | 2,556,740 | +13.2% | 206,764 | 12.37 |
| 2025-01-31 | 2,258,118 | -1.6% | 136,150 | 16.59 |
| 2025-01-15 | 2,293,765 | +6.8% | 212,254 | 10.81 |
| 2024-12-31 | 2,148,311 | -8.6% | 296,353 | 7.25 |
| 2024-12-13 | 2,350,578 | +27.8% | 278,446 | 8.44 |
| 2024-11-29 | 1,839,789 | -12.8% | 234,292 | 7.85 |
| 2024-11-15 | 2,111,003 | -2.1% | 350,267 | 6.03 |
| 2024-10-31 | 2,155,747 | +5.2% | 171,455 | 12.57 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of ANIP volume is 56.5%, up 2.1 points over the last five sessions. Over the last 30 readings it ranged from 40.0% (9 October 2026) to 76.6% (30 October 2026). The latest reading is in line with the 30-session average of 58.1%, on 202K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 114K | 202K | 56.5% | 0 |
| 2026-10-30 | 66K | 86K | 76.6% | 0 |
| 2026-10-29 | 71K | 98K | 72.8% | 0 |
| 2026-10-28 | 117K | 174K | 67.2% | 0 |
| 2026-10-27 | 69K | 99K | 70.0% | 0 |
| 2026-10-26 | 50K | 92K | 54.4% | 0 |
| 2026-10-23 | 57K | 88K | 64.5% | 0 |
| 2026-10-22 | 218K | 291K | 74.8% | 0 |
| 2026-10-21 | 44K | 108K | 40.2% | 0 |
| 2026-10-20 | 30K | 66K | 45.4% | 0 |
| 2026-10-19 | 47K | 81K | 58.1% | 0 |
| 2026-10-16 | 82K | 138K | 59.4% | 0 |
| 2026-10-15 | 46K | 103K | 44.3% | 0 |
| 2026-10-14 | 67K | 95K | 70.7% | 0 |
| 2026-10-13 | 64K | 142K | 45.2% | 0 |
| 2026-10-12 | 70K | 133K | 52.3% | 1 |
| 2026-10-09 | 96K | 240K | 40.0% | 0 |
| 2026-10-08 | 129K | 246K | 52.5% | 0 |
| 2026-10-07 | 81K | 186K | 43.8% | 0 |
| 2026-10-06 | 59K | 107K | 54.7% | 0 |
| 2026-10-05 | 48K | 94K | 51.3% | 0 |
| 2026-10-02 | 47K | 100K | 47.1% | 0 |
| 2026-10-01 | 62K | 93K | 66.6% | 0 |
| 2026-09-30 | 48K | 87K | 54.9% | 0 |
| 2026-09-29 | 65K | 112K | 58.6% | 6 |
| 2026-09-28 | 93K | 128K | 72.1% | 0 |
| 2026-09-25 | 40K | 81K | 48.9% | 0 |
| 2026-09-24 | 80K | 126K | 63.9% | 0 |
| 2026-09-23 | 123K | 197K | 62.5% | 0 |
| 2026-09-22 | 101K | 137K | 74.2% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 9 October 2026, the fails-to-deliver balance in ANIP is 16 shares, down 434 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (24 March 2026) to 8,188 shares (25 August 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-09 | 16 | $71.98 | $1K |
| 2026-10-06 | 450 | $72.58 | $33K |
| 2026-09-18 | 316 | $75.39 | $24K |
| 2026-09-17 | 2,218 | $73.59 | $163K |
| 2026-09-16 | 1,138 | $72.11 | $82K |
| 2026-09-15 | 2,827 | $70.40 | $199K |
| 2026-09-09 | 5,179 | $70.23 | $364K |
| 2026-08-25 | 8,188 | $74.17 | $607K |
| 2026-08-13 | 1 | $75.12 | $75 |
| 2026-08-03 | 29 | $79.24 | $2K |
| 2026-07-23 | 217 | $77.61 | $17K |
| 2026-07-22 | 217 | $79.15 | $17K |
| 2026-06-30 | 12 | $84.12 | $1K |
| 2026-06-26 | 14 | $83.28 | $1K |
| 2026-06-15 | 367 | $81.68 | $30K |
| 2026-05-21 | 6 | $82.00 | $492 |
| 2026-05-19 | 19 | $79.34 | $2K |
| 2026-05-14 | 61 | $80.88 | $5K |
| 2026-05-12 | 6 | $78.71 | $472 |
| 2026-05-05 | 82 | $82.32 | $7K |
| 2026-05-01 | 7 | $79.45 | $556 |
| 2026-04-23 | 6 | $80.14 | $481 |
| 2026-04-20 | 195 | $80.92 | $16K |
| 2026-04-15 | 400 | $78.29 | $31K |
| 2026-04-14 | 643 | $78.31 | $50K |
| 2026-04-13 | 55 | $78.36 | $4K |
| 2026-04-10 | 12 | $80.14 | $962 |
| 2026-04-08 | 481 | $79.47 | $38K |
| 2026-03-24 | 1 | $73.92 | $74 |
| 2026-02-27 | 653 | $77.15 | $50K |
Insider trades
SEC Form 4, newest first. JSONInsiders at ANIP reported 11 open-market sells worth $2.2M in the last 90 days and no open-market buys. Latest filing: CAREY STEPHEN P. (SVP & CFO) on 2026-10-29.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-29 | CAREY STEPHEN P. | SVP & CFO | Sell | 3K | $72.87 | $208K | 166K |
| 2026-10-15 | Lalwani Nikhil | PRESIDENT & CEO | Sell | 5K | $71.89 | $388K | 334K |
| 2026-10-13 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $73.59 | $37K | 73K |
| 2026-09-29 | CAREY STEPHEN P. | SVP & CFO | Sell | 3K | $73.00 | $208K | 169K |
| 2026-09-15 | Lalwani Nikhil | PRESIDENT & CEO | Sell | 5K | $71.00 | $383K | 339K |
| 2026-09-14 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $70.79 | $35K | 74K |
| 2026-09-11 | Thoma Jeanne | Director | Sell | 1K | $71.53 | $72K | 27K |
| 2026-08-31 | CAREY STEPHEN P. | SVP & CFO | Sell | 3K | $72.80 | $207K | 172K |
| 2026-08-25 | Lalwani Nikhil | PRESIDENT & CEO | Sell | 5K | $74.30 | $401K | 344K |
| 2026-08-19 | Gosebruch Henry O | Director | Grant | 7K | $0.00 | $0 | 7K |
| 2026-08-13 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $75.48 | $38K | 74K |
| 2026-08-10 | Gutwerg Ori | SVP, GENERICS | Sell | 3K | $77.00 | $243K | 76K |
| 2026-07-29 | CAREY STEPHEN P. | SVP & CFO | Sell | 3K | $81.36 | $232K | 175K |
| 2026-07-18 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Tax withholding | 2K | $79.20 | $195K | 75K |
| 2026-07-13 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $81.84 | $41K | 77K |
| 2026-07-02 | CAREY STEPHEN P. | SVP & CFO | Sell | 3K | $86.00 | $285K | 178K |
| 2026-07-02 | CAREY STEPHEN P. | SVP & CFO | Exercise or conversion | 3K | $49.51 | $164K | 181K |
| 2026-06-29 | CAREY STEPHEN P. | SVP & CFO | Sell | 3K | $84.12 | $240K | 178K |
| 2026-06-12 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $82.03 | $41K | 78K |
| 2026-06-08 | HAUGHEY THOMAS | Director | Sell | 2K | $80.88 | $162K | 39K |
| 2026-06-05 | CAREY STEPHEN P. | SVP & CFO | Sell | 3K | $80.00 | $265K | 180K |
| 2026-06-05 | CAREY STEPHEN P. | SVP & CFO | Exercise or conversion | 3K | $49.51 | $164K | 184K |
| 2026-05-21 | Thoma Jeanne | Director | Grant | 4K | $0.00 | $0 | 28K |
| 2026-05-21 | Leonard Matthew J | Director | Grant | 4K | $0.00 | $0 | 11K |
| 2026-05-21 | Pera Antonio R | Director | Grant | 4K | $0.00 | $0 | 27K |
| 2026-05-21 | TANNENBAUM RENEE P | Director | Grant | 4K | $0.00 | $0 | 30K |
| 2026-05-21 | HAUGHEY THOMAS | Director | Grant | 4K | $0.00 | $0 | 41K |
| 2026-05-13 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $78.16 | $39K | 78K |
| 2026-05-13 | Walsh Patrick D | Director | Sell | 10K | $80.63 | $806K | 38K |
| 2026-05-12 | Gutwerg Ori | SVP, GENERICS | Sell | 3K | $79.50 | $220K | 79K |
| 2026-05-12 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell | 459 | $79.21 | $36K | 38K |
| 2026-05-11 | Lalwani Nikhil | PRESIDENT & CEO | Sell | 55K | $77.57 | $4.3M | 350K |
| 2026-05-11 | Walsh Patrick D | Director | Sell | 4K | $80.75 | $321K | 48K |
| 2026-04-13 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $77.95 | $39K | 79K |
| 2026-03-13 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $72.62 | $36K | 79K |
| 2026-03-13 | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 3K | $71.64 | $227K | 91K |
| 2026-03-11 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell | 5K | $74.91 | $357K | 39K |
| 2026-03-09 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 5K | $74.13 | $377K | 52K |
| 2026-03-09 | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 4K | $74.18 | $267K | 94K |
| 2026-03-07 | Mutz Christopher | HEAD OF RARE DISEASE | Tax withholding | 3K | $74.04 | $245K | 98K |
| 2026-03-07 | Gutwerg Ori | SVP, GENERICS | Tax withholding | 3K | $74.04 | $245K | 81K |
| 2026-03-07 | Lalwani Nikhil | PRESIDENT & CEO | Tax withholding | 17K | $74.04 | $1.3M | 405K |
| 2026-03-07 | CAREY STEPHEN P. | SVP & CFO | Tax withholding | 5K | $74.04 | $381K | 180K |
| 2026-03-06 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1K | $75.00 | $111K | 57K |
| 2026-03-06 | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 2K | $74.22 | $157K | 101K |
| 2026-03-05 | CAREY STEPHEN P. | SVP & CFO | Sell | 4K | $75.56 | $302K | 186K |
| 2026-03-05 | CAREY STEPHEN P. | SVP & CFO | Sell | 3K | $75.42 | $250K | 190K |
| 2026-03-05 | CAREY STEPHEN P. | SVP & CFO | Exercise or conversion | 3K | $49.51 | $164K | 193K |
| 2026-03-03 | Walsh Patrick D | Director | Sell | 6K | $74.23 | $445K | 52K |
| 2026-03-03 | Gutwerg Ori | SVP, GENERICS | Sell | 2K | $76.50 | $158K | 85K |
| 2026-03-02 | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 417 | $74.00 | $31K | 104K |
| 2026-02-28 | Davis Krista | SVP, CHIEF HR OFFICER | Tax withholding | 2K | $73.90 | $115K | 59K |
| 2026-02-28 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Tax withholding | 2K | $73.90 | $115K | 80K |
| 2026-02-28 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Tax withholding | 2K | $73.90 | $164K | 75K |
| 2026-02-28 | Mutz Christopher | HEAD OF RARE DISEASE | Tax withholding | 2K | $73.90 | $164K | 104K |
| 2026-02-28 | Gutwerg Ori | SVP, GENERICS | Tax withholding | 2K | $73.90 | $164K | 87K |
| 2026-02-28 | Lalwani Nikhil | PRESIDENT & CEO | Tax withholding | 12K | $73.90 | $903K | 422K |
| 2026-02-28 | CAREY STEPHEN P. | SVP & CFO | Tax withholding | 3K | $73.90 | $205K | 190K |
| 2026-02-28 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Tax withholding | 628 | $73.90 | $46K | 44K |
| 2026-02-26 | Davis Krista | SVP, CHIEF HR OFFICER | Grant | 11K | $77.15 | $834K | 60K |
| 2026-02-26 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Grant | 14K | $77.15 | $1.1M | 81K |
| 2026-02-26 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Grant | 11K | $77.15 | $858K | 77K |
| 2026-02-26 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Grant | 11K | $77.15 | $858K | 101K |
| 2026-02-26 | Mutz Christopher | HEAD OF RARE DISEASE | Grant | 21K | $77.15 | $1.6M | 106K |
| 2026-02-26 | Gutwerg Ori | SVP, GENERICS | Grant | 13K | $77.15 | $1.0M | 89K |
| 2026-02-26 | Lalwani Nikhil | PRESIDENT & CEO | Grant | 76K | $77.15 | $5.8M | 434K |
| 2026-02-26 | CAREY STEPHEN P. | SVP & CFO | Grant | 22K | $77.15 | $1.7M | 192K |
| 2026-02-26 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Grant | 6K | $77.15 | $465K | 44K |
| 2026-02-20 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 2K | $77.99 | $135K | 49K |
| 2026-02-20 | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 5K | $78.02 | $415K | 85K |
| 2026-02-19 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 2K | $77.53 | $162K | 51K |
| 2026-02-14 | Davis Krista | SVP, CHIEF HR OFFICER | Tax withholding | 1K | $77.36 | $100K | 53K |
| 2026-02-14 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Tax withholding | 2K | $77.36 | $138K | 68K |
| 2026-02-14 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Tax withholding | 2K | $77.36 | $133K | 66K |
| 2026-02-14 | Mutz Christopher | HEAD OF RARE DISEASE | Tax withholding | 2K | $77.36 | $186K | 90K |
| 2026-02-14 | Gutwerg Ori | SVP, GENERICS | Tax withholding | 2K | $77.36 | $146K | 76K |
| 2026-02-14 | Lalwani Nikhil | PRESIDENT & CEO | Tax withholding | 10K | $77.36 | $797K | 359K |
| 2026-02-14 | CAREY STEPHEN P. | SVP & CFO | Tax withholding | 2K | $77.36 | $189K | 170K |
| 2026-02-14 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Tax withholding | 485 | $77.36 | $38K | 38K |
| 2026-02-13 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $76.80 | $38K | 69K |
| 2026-02-12 | Davis Krista | SVP, CHIEF HR OFFICER | Tax withholding | 1K | $76.70 | $91K | 54K |
| 2026-02-12 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Tax withholding | 2K | $76.70 | $118K | 70K |
| 2026-02-12 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Tax withholding | 2K | $76.70 | $123K | 68K |
| 2026-02-12 | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 7K | $76.55 | $538K | 93K |
| 2026-02-12 | Mutz Christopher | HEAD OF RARE DISEASE | Tax withholding | 3K | $76.70 | $243K | 100K |
| 2026-02-12 | Gutwerg Ori | SVP, GENERICS | Tax withholding | 2K | $76.70 | $136K | 78K |
| 2026-02-12 | Lalwani Nikhil | PRESIDENT & CEO | Tax withholding | 12K | $76.70 | $896K | 369K |
| 2026-02-12 | CAREY STEPHEN P. | SVP & CFO | Tax withholding | 3K | $76.70 | $217K | 173K |
| 2026-02-12 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Tax withholding | 566 | $76.70 | $43K | 39K |
| 2026-02-11 | Davis Krista | SVP, CHIEF HR OFFICER | Tax withholding | 3K | $76.25 | $230K | 56K |
| 2026-02-11 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Tax withholding | 3K | $76.25 | $230K | 71K |
| 2026-02-11 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Tax withholding | 4K | $76.25 | $326K | 69K |
| 2026-02-11 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Tax withholding | 3K | $76.25 | $221K | 90K |
| 2026-02-11 | Mutz Christopher | HEAD OF RARE DISEASE | Tax withholding | 5K | $76.25 | $347K | 103K |
| 2026-02-11 | Gutwerg Ori | SVP, GENERICS | Tax withholding | 4K | $76.25 | $325K | 80K |
| 2026-02-11 | Lalwani Nikhil | PRESIDENT & CEO | Tax withholding | 31K | $76.25 | $2.3M | 381K |
| 2026-02-11 | CAREY STEPHEN P. | SVP & CFO | Tax withholding | 6K | $76.25 | $420K | 175K |
| 2026-02-11 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Tax withholding | 2K | $76.25 | $134K | 39K |
| 2026-01-13 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $84.33 | $42K | 74K |
| 2025-12-18 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 2K | $82.40 | $134K | 59K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON16 Form 144 notices on file for ANIP worth $11.1M at the prices reported; 5 in the last 90 days worth $1.8M. Latest: STEPHEN CAREY filed on 2026-10-29 to sell 8,550 shares ($613K) from 2026-10-29.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-29 | STEPHEN CAREYOfficer | 9K | $613K | 0.037% | 2026-10-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-10-15 | NIKHIL LALWANIDirector, Officer | 5K | $379K | 0.024% | 2026-10-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-15 | NIKHIL LALWANIDirector, Officer | 5K | $380K | 0.024% | 2026-09-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-11 | JEANNE THOMADirector | 1K | $71K | 0.004% | 2026-09-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-25 | NIKHIL LALWANIDirector, Officer | 5K | $401K | 0.024% | 2026-08-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-29 | STEPHEN P CAREYOfficer | 6K | $499K | 0.027% | 2026-07-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-07 | PATRICK WALSHDirector | 4K | $374K | 0.019% | 2026-07-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-08 | THOMAS HAUGHEYDirector | 2K | $162K | 0.009% | 2026-06-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-05 | STEPHEN P CAREYOfficer | 12K | $939K | 0.052% | 2026-06-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-13 | Walsh Patrick DDirector | 10K | $796K | 0.044% | 2026-05-13 | Charles Schwab Corp |
| 2026-05-11 | NIKHIL LALWANIOfficer, Director | 55K | $4.3M | 0.242% | 2026-05-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-11 | PATRICK WALSHDirector | 4K | $321K | 0.017% | 2026-05-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-05 | STEPHEN P CAREYOfficer | 7K | $552K | 0.033% | 2026-03-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-03 | PATRICK WALSHDirector | 6K | $445K | 0.027% | 2026-03-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-09 | RENATE PLAWNER TANNENBAUM 2024 RV TRUSTDirector | 2K | $146K | 0.008% | 2025-12-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-13 | PATRICK WALSHDirector | 9K | $751K | 0.038% | 2025-11-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON1 holder reports 5% or more of ANIP in its latest filing, on Schedule 13G (passive). The holder is BlackRock, Inc. at 12.8% of the class (2,899,843 shares), filed 2026-07-27 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-07-27 | 13G/Ano. 13 | BlackRock, Inc.parent holding company | 2.9M | 12.8% | 2026-06-30 |
| 2026-03-26 | 13G/Ano. 1 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2025-11-13 | 13G/Ano. 1 | Millennium Management LLCother entity | 65K | 0.3% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 1 | Millennium Group Management LLCother entity | 65K | 0.3% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 1 | Israel A. Englanderindividual | 65K | 0.3% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 1 | Integrated Core Strategies (US) LLCother entity | 54K | 0.2% | 2025-09-30 |
13F holders
Tracked managers holding ANIP at their latest 13F. JSON6 of the 30 tracked managers held ANIP at their latest 13F, $77.4M in total at quarter-end prices. Millennium Management is the largest at $42.0M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 1 added shares and 5 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 507K | $42.0M | 0.02% | -85K |
| D. E. Shaw & Co. | 2026-06-30 | 175K | $14.5M | 0.01% | -39K |
| Citadel Advisors | 2026-06-30 | 96K | $8.0M | 0.00% | -19K |
| Two Sigma Investments | 2026-06-30 | 64K | $5.3M | 0.00% | -33K |
| Renaissance Technologies | 2026-06-30 | 64K | $5.3M | 0.01% | -122K |
| AQR Capital Management | 2026-06-30 | 30K | $2.4M | 0.00% | +11K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Ani Pharmaceuticals reported revenue of $266.0M, up 25.9% from the same quarter a year earlier, and net income of $24.7M (1.05 diluted EPS). In FY 2025 it generated $185.2M of operating cash flow and spent $12.2M on buybacks and $1.2M on dividends. As of 2026-06-30, cash was $360.2M against $280.2M of debt.
- Cash
- $360.2M
- Debt
- $280.2M
- Equity
- $597.2M
- Total assets
- $1.49B
- Shares outstanding
- 24,422,240
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $266.0M | $24.7M | 9.3% | 1.05 |
| Q1 FY 2026 | 2026-03-31 | $237.5M | $29.5M | 12.4% | 1.28 |
| Q4 FY 2025derived | 2025-12-31 | $247.1M | $27.5M | 11.1% | n/a |
| Q3 FY 2025 | 2025-09-30 | $227.8M | $26.6M | 11.7% | 1.13 |
| Q2 FY 2025 | 2025-06-30 | $211.4M | $8.5M | 4.0% | 0.36 |
| Q1 FY 2025 | 2025-03-31 | $197.1M | $15.7M | 8.0% | 0.69 |
| Q4 FY 2024derived | 2024-12-31 | $190.6M | -$10.3M | -5.4% | n/a |
| Q3 FY 2024 | 2024-09-30 | $148.3M | -$24.2M | -16.3% | -1.27 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $883.4M | $78.3M | $185.2M | $13.8M | $12.2M | $1.2M |
| FY 2024 | 2024-12-31 | $614.4M | -$18.5M | $64.0M | $16.2M | $11.0M | $1.6M |
| FY 2023 | 2023-12-31 | $486.8M | $18.8M | $119.0M | $8.9M | $5.0M | $1.6M |
| FY 2022 | 2022-12-31 | $316.4M | -$47.9M | -$31.2M | $8.9M | $2.0M | $1.6M |
| FY 2021 | 2021-12-31 | $216.1M | -$42.6M | $3.3M | $2.6M | $890K | $190K |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2013-02-28 from the cover page.
What this page is
Ani Pharmaceuticals in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Ani Pharmaceuticals (ANIP), SEC CIK 1023024, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-09.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-29.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-07-27.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-07.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-29.JSON and CSV
- Company record
- EDGAR filing index for CIK 1023024Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of ANIP is sold short?
3,472,078 shares were held short at the 2026-10-15 settlement, 10.1 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ANIP's daily short volume?
On 2026-11-02, 114,251 of the 202,171 ANIP shares reported to FINRA were sold short, 56.5% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ANIP have fails to deliver?
The SEC's latest file shows 16 ANIP shares failed to deliver at settlement 2026-10-09. Fails are reported per settlement date and published twice a month with a lag.
Are ANIP insiders buying or selling?
Insiders at ANIP reported 11 open-market sells worth $2.2M in the last 90 days and no open-market buys. Latest filing: CAREY STEPHEN P. (SVP & CFO) on 2026-10-29.
Have ANIP insiders filed to sell?
16 Form 144 notices on file for ANIP worth $11.1M at the prices reported; 5 in the last 90 days worth $1.8M. Latest: STEPHEN CAREY filed on 2026-10-29 to sell 8,550 shares ($613K) from 2026-10-29.
Who owns 5% or more of ANIP?
1 holder reports 5% or more of ANIP in its latest filing, on Schedule 13G (passive). The holder is BlackRock, Inc. at 12.8% of the class (2,899,843 shares), filed 2026-07-27 for an event on 2026-06-30.
What did ANIP report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Ani Pharmaceuticals reported revenue of $266.0M, up 25.9% from the same quarter a year earlier, and net income of $24.7M (1.05 diluted EPS). In FY 2025 it generated $185.2M of operating cash flow and spent $12.2M on buybacks and $1.2M on dividends. As of 2026-06-30, cash was $360.2M against $280.2M of debt.
Which tracked 13F managers own ANIP?
6 of the 30 tracked 13F managers held ANIP shares at their latest filing, $77.4M in all. The largest: Izzy Englander's Millennium Management (507K shares, $42.0M), D. E. Shaw & Co. (175K shares, $14.5M), Ken Griffin's Citadel Advisors (96K shares, $8.0M), Two Sigma Investments (64K shares, $5.3M), Renaissance Technologies (64K shares, $5.3M), Cliff Asness's AQR Capital Management (30K shares, $2.4M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.